Altimmune, Inc.
ALTDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
ALT Earnings Report
EPS Est: $-0.15 | FQ end 2026-06
How ALT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALT-801 | Phase 2 | Obesity/Overweight | - | - |
Pemvidutide | Phase 2 | Alcohol Use Disorder (AUD) | - | - |
NasoVAX | Phase 2 | Influenza | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Altimmune, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Altimmune, Inc.'s (ALT) pipeline across Phase 2. Its lead program is ALT-801 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Altimmune, Inc.'s next FDA catalyst?→
Altimmune, Inc.'s (ALT) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALT biotech catalysts?→
Add ALT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Altimmune, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.